Intra-Cellular Therapies Inc

NASDAQ:ITCI   3:59:52 PM EDT
33.16
-0.62 (-1.84%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)2.61B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$12.02 Million
Adjusted EPS-$0.86
See more estimates
10-Day MA$33.02
50-Day MA$28.32
200-Day MA$23.85
See more pivots

Intra-Cellular Therapies, Inc. Stock, NASDAQ:ITCI

430 EAST 29TH STREET, NEW YORK, NY 10016
United States of America
Phone: 212-923-3344
Number of Employees: 73

Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.